Congenital Heart Block– Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Congenital heart block or
atrioventricular block is a loss in the normal function of the cardiac
electroconductive pathways that connect the sinoatrial node (SA node) to the
ventricles via conduction through the atrioventricular node (AV node). The
congenital heart block associated with neonatal lupus is considered a form of passively
acquired autoimmune disease in which maternal autoantibodies to the
intracellular ribonucleoproteins Ro (SS-A) and La (SS-B) cross the placenta and
injure the previously normal fetal heart. Women with serum titers of anti-Ro
antibody carry a 3% risk of having a child with neonatal lupus syndrome.
Recurrence rates are about 18%. Chronic idiopathic fibrosis and sclerosis of
the conduction system in Lenegre's disease cause half of the cases. Another
common cause is ischemic heart disease, responsible for 40% of cases. It is
associated with hypertrophic obstructive cardiomyopathy and infiltrative
diseases like sarcoidosis and amyloidosis. First-degree congenital blocks can
originate from various locations within the conduction system. The level of conduction
delay includes the atrium, AV node (most common in first-degree block), Bundle
of His, fascicles, Bundle Branches, and Purkinje system. Mobitz type I
second-degree congenital block originates from conduction system disease below
the level of the atrioventricular node. In third-degree atrioventricular block,
no impulses will reach the ventricle and occur in the atrioventricular node or
the intranodal specialized conduction system.
- The incidence of congenital heart block
ranges from 1 to 2 cases per 50,000 live births, associated with high
mortality and morbidity in the USA.
Thelansis’s “Congenital Heart Block
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2021 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Congenital Heart Block treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Congenital Heart Block across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Congenital Heart Block Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment